Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 15/20 | 0.47 |
| ▸ | PRKAA1 | Q13131 | 15/20 | 0.47 |
| ▸ | PRKAB1 | Q9Y478 | 15/20 | 0.47 |
| ▸ | PRKAA2 | P54646 | 14/20 | 0.47 |
| ▸ | PRKAB2 | O43741 | 13/20 | 0.47 |
| ▸ | PRKAG3 | Q9UGI9 | 13/20 | 0.47 |
| ▸ | PRKAG2 | Q9UGJ0 | 13/20 | 0.47 |
| ▸ | TDO2 | P48775 | 3/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31748607 | 0.88 | PRKAG1 (0.61) | PRKAG1PRKAA1PRKAB1PRKAA2PRKAB2 | |
| SCHEMBL31748557 | 0.85 | TDO2 (0.39) | PRKAG1PRKAA1PRKAB1PRKAA2PRKAB2 | |
| SCHEMBL31748523 | 0.80 | PRKAG1 (0.60) | PRKAG1PRKAA1PRKAB1PRKAA2PRKAB2 | |
| SCHEMBL31748450 | 0.73 | PRKAB2 (0.48) | PRKAG1PRKAA1PRKAB1PRKAA2PRKAB2 | |
| SCHEMBL31748356 | 0.71 | PRKAB2 (0.43) | PRKAG1PRKAA1PRKAB1PRKAA2PRKAB2 | |
| SCHEMBL31748527 | 0.71 | PRKAG1 (0.44) | PRKAG1PRKAA1PRKAB1PRKAA2PRKAB2 | |
| SCHEMBL31748633 | 0.69 | GRIK1 (0.31) | DHODH | |
| SCHEMBL31748478 | 0.68 | PRKAB2 (0.42) | PRKAG1PRKAA1PRKAB1PRKAA2PRKAB2 | |
| SCHEMBL31748613 | 0.67 | PRKAG1 (0.37) | PRKAG1PRKAA1PRKAB1TDO2DHODH | |
| SCHEMBL31748496 | 0.66 | PRKAB2 (0.61) | PRKAG1PRKAA1PRKAB1PRKAA2PRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | PRKAG1 6/4885PRKAA1 8/4885PRKAB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.